Doctor of Osteopathy Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Merle Turner

General Practice Chandler, AZ Doctor of Osteopathy

NPI 1659463552 CMS profile 120835

2905 W Warner Rd, Suite 12, Chandler, AZ 85224

Open in the dashboard

General payments

$7,473

122 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$7,739 paid to institutions, not to them · program year 2019

Through program year 2023, Merle Turner of Chandler, AZ is reported in the CMS Open Payments database as having received $7,473 across 122 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $7,739 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $5,820 23
2022 General $429 22
2021 General $300 14
2020 General $116 8
2019 General $808 55

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Merle Turner
  • General Practice median
  • Middle half of General Practice
  • National median

In program year 2025, general payments to Merle Turner were reported at $0. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.

Show as a table
Year Merle Turner General Practice median Middle half National median
2019 $808 $107 $37–$285 $163
2020 $116 $75 $25–$213 $114
2021 $300 $93 $30–$272 $132
2022 $429 $103 $36–$279 $149
2023 $5,820 $106 $34–$276 $160
2024 $0 $114 $39–$290 $164
2025 $0 $106 $35–$292 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Astellas Pharma US Inc $5,568 8 payments
  2. Novo Nordisk Inc $264 18 payments
  3. AstraZeneca Pharmaceuticals LP $209 17 payments
  4. Lilly USA, LLC $208 15 payments
  5. Pfizer Inc. $147 8 payments
  6. Lucid Diagnostics Inc. $107 3 payments
  7. Abbott Laboratories $86 4 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $85 6 payments
  9. AbbVie, Inc. $81 5 payments
  10. GlaxoSmithKline, LLC. $80 5 payments
  11. Other $638 33 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,695 2 payments
  2. Food and Beverage $2,279 117 payments
  3. Travel and Lodging $479 2 payments
  4. Entertainment $20 1 payment
Products named General payments · program years 2019–2023
  1. Veozah $5,552 7 payments
  2. Ozempic $172 13 payments
  3. TRULICITY $109 8 payments
  4. COLOGUARD $107 6 payments
  5. RYBELSUS $94 6 payments
  6. XIFAXAN $85 6 payments
  7. FARXIGA $81 6 payments
  8. JARDIANCE $80 6 payments
  9. QUVIVIQ $77 5 payments
  10. XARELTO $68 1 payment
  11. Other $1,662 99 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

128

Median for General Practice: 1,105

Drug cost

$2,154

Median for General Practice: $48,734

Branded share of claims

8.6%

Median for General Practice: 17.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 11 $678
Atorvastatin Calcium Generic 33 $540
Gabapentin Generic 24 $251
Donepezil Hcl Generic 22 $224
Memantine Hcl Generic 11 $157
Levothyroxine Sodium Generic 14 $155
Escitalopram Oxalate Generic 13 $147

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,210 Part D prescribers listed as General Practice; they describe a distribution and say nothing about conduct.

Records

122 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other General Practice in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record